NUMAFERM GmbH
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
NUMAFERM GmbH - overview
Established
2017
Location
Dusseldorf, -, Germany
Primary Industry
Biotechnology
About
NUMAFERM GmbH is a biotechnology company focused on producing peptides, proteins, and pepteins utilizing advanced platforms like Numascreen™ and Numatech™. Founded in 2017 in Dusseldorf, Germany, Numaferm GmbH specializes in creating high-diversity phage display libraries for applications in pharmaceuticals, agriculture, and aquaculture. Philipp Buerling is the founder, with Christian Schwarz serving as CEO. The company raised seed financing in May 2017 led by Evonik Venture Capital, alongside participation from the European Investment Fund and High-Tech Gründerfonds.
NUMAFERM GmbH specializes in the production of peptides, pepteins, and proteins through its innovative platforms, namely Numascreen™ and Numatech™. The core offering encompasses high-diversity phage display libraries that exceed 1 billion peptides, facilitating the discovery and optimization of high-affinity binders tailored for various applications. The Numatech™ platform ensures rapid large-scale peptide expression and timely delivery of high-quality products, serving a diverse customer base including pharmaceutical companies and agricultural firms primarily in Europe and North America. Numaferm generates revenue through structured partnerships and commercial agreements, particularly in the pharmaceutical and agricultural sectors.
Their business model includes B2B contracts for lead discovery services and peptide production, often involving fixed pricing for specific projects or milestone-based payments. Their flagship products, such as Teriparatide and the proprietary Numascreen™ phage display libraries, are pivotal to their revenue streams, supported by strong client relationships and ongoing collaborations. Numaferm plans to introduce new products in the coming years, expanding its offerings within the peptide and protein markets. The company aims to penetrate new geographical regions, focusing on growth in Asia and South America by 2025.
Recent funding from the Seed round will support these initiatives, enhancing their product development capabilities and enabling strategic market expansions.
Current Investors
European Investment Fund, High-Tech Gruenderfonds, Evonik Venture Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.numaferm.com
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
NUMAFERM GmbH - financials
| Fiscal Year Ended | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|
| Revenue (USD) | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - |
| EBITDA (USD) | - | - | - | - |
| Operating Income (USD) | - | - | - | - |
| Operating Margin | - | - | - | - |
| % EBITDA Margin | - | - | - | - |
| NET Income (USD) | (406,421.6) | - | - | - |
| % Net Margin | - | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.